Prediction: Hydroxychloroquine will be prove to be the antidote to the vaccine once all is revealed.
You're viewing a single comment thread. View all comments, or full comment thread.
Comments (45)
sorted by:
ADE/cytokine storm after receiving the vaccines leading to ICU admission and even death is currently in trials and has shown some success. The medication is leronlimab. Do some reading on it from multiple sources and you will see what I am talking about!
Leronlimab is a game changer, which is why it's being attacked relentlessly from all sides.
Got any links? From the FDA site "With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do NOT support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints"
It should have been given EUA since it is safe and did show possible benefit. This is a link for a case study where a patient was on ECMO for 79 days and then received leronlimab. They are delaying it or trying to keep it hidden.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985604/pdf/main.pdf
It’s the severe illness that is important, most cases are mild/moderate. They are currently doing stage 3 clinical trials in Brazil. The FDA can say whatever it wants to say. With regards to the critically ill patients, the drug improved mortality over the placebo/Standard-of-Care arm by 78% after 7 days, and 82% after 14 days.
There were a few mistakes whether intentional or not in the FDA statement. For CD12 study the FDA wrote “also failed to find any effect of the drug on the primary study endpoint… or on any of the secondary endpoints.” This is simply not true. Mortality at 14 days of treatment for the critically ill was a secondary endpoint. Leronlimab’s mortality figures for the critically ill at 14 days were an 82% improvement over the Standard-of-Care arm of the study. This is a huge effect. But the FDA wants you to think there is no effect.
The FDA also would not let the trial give four total doses (once per week) over one month. Instead the FDA allowed them to give only two doses. Again this is why the 28 day mortality rate was not significant in the small trial and a larger trial will be completed.
The FDA essentially changed the design study to alter the results. They then played down the potential of the drug in a dog and pony statement!